HK1118716A1 - Method and composition for treating central nervous system disorders - Google Patents

Method and composition for treating central nervous system disorders

Info

Publication number
HK1118716A1
HK1118716A1 HK08110344.4A HK08110344A HK1118716A1 HK 1118716 A1 HK1118716 A1 HK 1118716A1 HK 08110344 A HK08110344 A HK 08110344A HK 1118716 A1 HK1118716 A1 HK 1118716A1
Authority
HK
Hong Kong
Prior art keywords
composition
nervous system
central nervous
system disorders
treating central
Prior art date
Application number
HK08110344.4A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HK1118716A1 publication Critical patent/HK1118716A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK08110344.4A 2005-01-27 2008-09-18 Method and composition for treating central nervous system disorders HK1118716A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64700805P 2005-01-27 2005-01-27
PCT/JP2006/301704 WO2006080549A2 (fr) 2005-01-27 2006-01-26 Procede et composition de traitement de troubles du systeme nerveux central

Publications (1)

Publication Number Publication Date
HK1118716A1 true HK1118716A1 (en) 2009-02-20

Family

ID=36740907

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110344.4A HK1118716A1 (en) 2005-01-27 2008-09-18 Method and composition for treating central nervous system disorders

Country Status (20)

Country Link
US (2) US8202909B2 (fr)
EP (2) EP1841433B1 (fr)
JP (1) JP5147404B2 (fr)
KR (1) KR101354771B1 (fr)
CN (1) CN101146541B (fr)
AR (1) AR055846A1 (fr)
AU (1) AU2006209072B2 (fr)
BR (1) BRPI0607084A2 (fr)
CA (1) CA2595898C (fr)
DK (1) DK1841433T3 (fr)
ES (1) ES2375082T3 (fr)
HK (1) HK1118716A1 (fr)
IL (1) IL184578A (fr)
NO (1) NO340257B1 (fr)
NZ (1) NZ556710A (fr)
PL (1) PL1841433T3 (fr)
PT (1) PT1841433E (fr)
RU (1) RU2440338C2 (fr)
TW (1) TWI384988B (fr)
WO (1) WO2006080549A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
MX339727B (es) * 2007-07-19 2016-06-06 R-Tech Ueno Ltd Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto.
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CA2813839C (fr) 2010-10-15 2017-03-21 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Procedes de preparation de lubiprostone
EP2667875A4 (fr) * 2011-01-24 2014-07-30 Inceptum Res & Therapeutics Inc Compositions comprenant une prostaglandine pour le traitement de pathologies neuropsychiatriques
KR20140043075A (ko) * 2011-04-19 2014-04-08 수캄포 아게 사이토카인 활성의 조절 방법
RU2648474C2 (ru) * 2011-08-05 2018-03-26 Сукампо Аг Способ лечения шизофрении
WO2014159679A1 (fr) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour utiliser la lubiprostone pour absorber un fluide depuis l'espace sous-rétinien
JP6348229B2 (ja) * 2014-10-21 2018-06-27 ユニバーシタット デ レス イレス バレアレス ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120243A (en) 1970-03-09 1968-07-17 Samuelsson Bengt Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr) 1971-07-14 1973-01-15 American Cyanamid Co Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) * 1975-09-02 1977-07-27 Upjohn Co Prostanoic acid derivatives
SU845774A3 (ru) 1976-04-20 1981-07-07 Фармиталия Карло Эрба С.П.А. (Фирма) Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
CA1322749C (fr) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandines de la serie d, et tranquilisants et soporifiques en contenant
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2030345C (fr) 1989-11-22 1998-12-08 Ryuji Ueno Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques
ES2069821T3 (es) 1990-02-26 1995-05-16 R Tech Ueno Ltd Nuevas 15-deshidroxi-16-oxoprostaglandinas.
TW224942B (fr) 1990-04-04 1994-06-11 Adka Ueno Kk
JPH04187637A (ja) * 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
JPH07113012B2 (ja) 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (fr) 1994-06-03 2004-08-10 Ryuji Ueno Agent therapeutique pour les affections hepatobiliaires
EP0857718B1 (fr) 1996-06-10 2002-08-14 Sucampo AG Antagoniste de l'endotheline
CA2279267C (fr) 1997-11-28 2010-01-12 R-Tech Ueno, Ltd. Utilisation des composes 15-cetaprostaglandine e comme antagoniste de l'endotheline
JP3703004B2 (ja) 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
EP1267882B1 (fr) * 2000-03-24 2009-04-15 Sucampo AG Prostaglandines pour le traitement des maladies des yeux provoqués par des rayons lumineux comme la photoretinite
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) * 2003-09-08 2005-08-17 秦正红 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

Also Published As

Publication number Publication date
CN101146541B (zh) 2012-04-11
NO20074332L (no) 2007-10-17
PL1841433T3 (pl) 2012-07-31
KR20070107065A (ko) 2007-11-06
RU2007132081A (ru) 2009-03-10
WO2006080549A3 (fr) 2007-07-05
TWI384988B (zh) 2013-02-11
TW200642690A (en) 2006-12-16
EP2332545A1 (fr) 2011-06-15
EP1841433A2 (fr) 2007-10-10
BRPI0607084A2 (pt) 2009-08-04
EP1841433B1 (fr) 2011-11-30
RU2440338C2 (ru) 2012-01-20
NO340257B1 (no) 2017-03-27
CA2595898C (fr) 2015-04-28
DK1841433T3 (da) 2012-01-16
CN101146541A (zh) 2008-03-19
IL184578A0 (en) 2007-10-31
US8202909B2 (en) 2012-06-19
CA2595898A1 (fr) 2006-08-03
KR101354771B1 (ko) 2014-01-22
US20120225938A1 (en) 2012-09-06
US20060194880A1 (en) 2006-08-31
ES2375082T3 (es) 2012-02-24
JP5147404B2 (ja) 2013-02-20
AR055846A1 (es) 2007-09-12
JP2008528440A (ja) 2008-07-31
IL184578A (en) 2015-02-26
PT1841433E (pt) 2012-02-01
WO2006080549A2 (fr) 2006-08-03
AU2006209072A1 (en) 2006-08-03
AU2006209072B2 (en) 2011-02-24
NZ556710A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
HK1118716A1 (en) Method and composition for treating central nervous system disorders
IL187480A0 (en) Method and composition for treating inflammatory disorders
ZA200610661B (en) Compositions and methods for treating neurological disorders
IL179766A0 (en) Compositions and methods using same for treating neurodegenerative disorders
IL180342A0 (en) Compositions and methods for treating eye disorders and conditions
EP2083857A4 (fr) Procédés pour traiter des troubles en rapport avec le mica
EP1603548A4 (fr) Composition et methode de traitement de troubles neurodegeneratifs
IL186450A0 (en) Methods for treating anxiety related disorders
EP1651164A4 (fr) Composition et methode pour traiter des troubles neurologiques
EP2170309A4 (fr) Procédés et compositions pour le traitement de troubles
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
IL188988A0 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
PT2374472T (pt) Composições e métodos para o tratamento de afeções oftalmológicas
IL185861A0 (en) Method and composition for treating mucosal disorders
GB0617734D0 (en) Method of treating peripheral nerve disorders
ZA200804951B (en) Compositions and methods for treating CNS disorders
IL180732A0 (en) Method for treating nervous system disorders and conditions
IL193697A0 (en) Methods for treating cognitive and other disorders
ZA200700578B (en) Method for treating nervous system disorders and conditions
EP1898921A4 (fr) Compositions et methodes servant a traiter les troubles du sommeil
ZA200708543B (en) Methods for treating anxiety related disorders
ZA200700583B (en) Method for treating nervous system disorders and conditions
EP1942909A4 (fr) Méthodes de traitement de troubles respiratoires
EP1755637A4 (fr) Methodes destinees a prevenir ou traiter des maladies osseuses
ZA200708408B (en) Method and composition for treating mucosal disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210126